John M. Evans - Jan 30, 2025 Form 4 Insider Report for Beam Therapeutics Inc. (BEAM)

Role
CEO, Director
Signature
By: /s/ Christine Bellon, Attorney-in-fact
Stock symbol
BEAM
Transactions as of
Jan 30, 2025
Transactions value $
-$802,484
Form type
4
Date filed
2/3/2025, 04:05 PM
Previous filing
Oct 2, 2024
Next filing
Apr 2, 2025
SEC
View on sec.gov
This filing has been restated, see here for the amended filing

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BEAM Common Stock Sale -$797K -29.8K -3.17% $26.75 909K Jan 30, 2025 Direct F1, F2
transaction BEAM Common Stock Sale -$5.46K -200 -0.02% $27.28 909K Jan 30, 2025 Direct F1
holding BEAM Common Stock 103K Jan 30, 2025 By John M. Evans, III 2018 Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BEAM Stock Option (Right to Buy) Award $0 +155K $0.00 155K Jan 31, 2025 Common Stock 155K $25.92 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $26.26 to $27.21 inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with BEAM through each vesting date.